RSV-A and RSV-B Show Distinct Antibody Susceptibility Patterns Despite Vaccine Development
A new study of 133 RSV clinical samples from 2022-2024 found that RSV-A and RSV-B subtypes differ in their susceptibility to monoclonal antibodies and vaccine-induced immunity. RSV-A isolates were less susceptible to multiple antibodies than RSV-B, and antibodies from RSV-A vaccination showed reduced effectiveness against contemporary RSV-B strains. The findings suggest that multivalent vaccines targeting both subtypes may be necessary to overcome subtype-specific immune responses.
Researchers analyzed viral genome sequences and conducted phenotypic testing on representative RSV isolates collected during the 2022-2023 and 2023-2024 seasons to understand how current monoclonal antibodies and vaccines perform against circulating strains. While all isolates retained sensitivity to the monoclonal antibodies tested and no mutations were detected in antibody binding sites, the study revealed important antigenic differences between subtypes: RSV-A isolates clustered together with lower neutralization by certain antibodies like MPE8 and 101F, while RSV-B isolates formed a distinct cluster with higher susceptibility. In animal models, vaccination with RSV-A alone produced strong responses to RSV-A strains but diminished activity against contemporary RSV-B isolates, whereas RSV-B vaccination showed more balanced neutralization across both subtypes. Combined RSV-A and RSV-B immunization produced uniformly strong responses to all isolates tested, suggesting that multivalent vaccine approaches may overcome the subtype-specific antibody polarization observed with single-subtype exposure.
What's missing
The study's limitations include reliance on a rabbit vaccination model rather than human data, which may not fully reflect immune responses in vaccinated or naturally infected humans; the sample size of 8 isolates selected for phenotypic testing from 133 sequenced samples; and the lack of data on how these findings translate to clinical protection or real-world vaccine effectiveness.
What different sources said
- bioRxivCenter
Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.